{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:41:19Z","timestamp":1793234479074,"version":"4.5.0"},"reference-count":107,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T00:00:00Z","timestamp":1496707200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Children"],"abstract":"<jats:p>Due to the epidemic of obesity across the world, nonalcoholic fatty liver disease (NAFLD) has become one of the most prevalent chronic liver disorders in children and adolescents. NAFLD comprises a spectrum of fat-associated liver conditions that can result in end-stage liver disease and the need for liver transplantation. Simple steatosis, or fatty liver, occurs early in NAFLD and may progress to nonalcoholic steatohepatitis, fibrosis and cirrhosis with increased risk of hepatocellular carcinoma. The mechanism of the liver injury in NAFLD is currently thought to be a \u201cmultiple-hit process\u201d where the first \u201chit\u201d is an increase in liver fat, followed by multiple additional factors that trigger the inflammatory activity. At the onset of disease, NAFLD is characterized by hepatic triglyceride accumulation and insulin resistance. Liver fat accumulation is associated with increased lipotoxicity from high levels of free fatty acids, free cholesterol and other lipid metabolites. As a consequence, mitochondrial dysfunction with oxidative stress and production of reactive oxygen species and endoplasmic reticulum stress-associated mechanisms, are activated. The present review focuses on the relationship between intra-cellular lipid accumulation and insulin resistance, as well as on lipid and lipoprotein metabolism in NAFLD.<\/jats:p>","DOI":"10.3390\/children4060046","type":"journal-article","created":{"date-parts":[[2017,6,6]],"date-time":"2017-06-06T10:53:09Z","timestamp":1496746389000},"page":"46","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":93,"title":["The Role of Lipid and Lipoprotein Metabolism in Non\u2010Alcoholic Fatty Liver Disease"],"prefix":"10.3390","volume":"4","author":[{"given":"Francesco","family":"Perla","sequence":"first","affiliation":[{"name":"Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, 00161, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizia","family":"Prelati","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, 00161, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michela","family":"Lavorato","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, 00161, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Visicchio","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, 00161, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Anania","sequence":"additional","affiliation":[{"name":"Policlinico Umberto I Hospital, Sapienza University of Rome, Rome, 00161, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2017,6,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1056\/NEJMra011775","article-title":"Nonalcoholic fatty liver disease","volume":"346","author":"Angulo","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.pcl.2011.09.005","article-title":"Advances in pediatric nonalcoholic fatty liver disease","volume":"58","author":"Mencin","year":"2011","journal-title":"Pediatr. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1002\/hep.23119","article-title":"Advances in pediatric nonalcoholic fatty liver disease","volume":"50","author":"Loomba","year":"2009","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Anderson, E.L., Howe, L.D., Jones, H.E., Higgins, J.P., Lawlor, D.A., and Fraser, A. (2015). The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0140908"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1053\/j.gastro.2016.03.009","article-title":"Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease","volume":"150","author":"Nobili","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.cgh.2008.11.005","article-title":"Long-Term Follow-Up of Patients With Nonalcoholic Fatty Liver","volume":"7","author":"Rafiq","year":"2009","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1017\/S0029665113001249","article-title":"Ectopic fat, insulin resistance and non-alcoholic fatty liver disease","volume":"72","author":"Byrne","year":"2013","journal-title":"Proc. Nutr. Soc."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.1016\/S0140-6736(10)60408-4","article-title":"Lipid-induced insulin resistance: Unraveling the mechanism","volume":"375","author":"Samuel","year":"2010","journal-title":"Lancet"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1002\/hep.22858","article-title":"Glucose dysregulation and hepatic steatosis in obese adolescents: Is there a link?","volume":"49","author":"Cali","year":"2009","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.2337\/dc10-0284","article-title":"Central role of fatty liver in the pathogenesis of insulin resistance in obese adolescents","volume":"33","author":"Cali","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1161\/ATVBAHA.107.147538","article-title":"Fatty liver: A novel component of the metabolic syndrome","volume":"28","author":"Kotronen","year":"2008","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1161\/CIRCULATIONAHA.107.739920","article-title":"Cardiovascular risk factors and the metabolic syndrome in pediatric nonalcoholic fatty liver disease","volume":"118","author":"Schwimmer","year":"2008","journal-title":"Circulation"},{"key":"ref_13","first-page":"3082","article-title":"Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk","volume":"17","author":"Pacifico","year":"2011","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1056\/NEJMra0912063","article-title":"Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease","volume":"363","author":"Targher","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/hep.23890","article-title":"Functional and morphological vascular changes in pediatric nonalcoholic fatty liver disease","volume":"52","author":"Pacifico","year":"2010","journal-title":"Hepatology"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/hep.26610","article-title":"Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease","volume":"59","author":"Pacifico","year":"2014","journal-title":"Hepatology"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"8078","DOI":"10.3748\/wjg.v22.i36.8078","article-title":"Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions","volume":"22","author":"Clemente","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"32345","DOI":"10.1074\/jbc.M313478200","article-title":"Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease","volume":"279","author":"Samuel","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1172\/JCI30400","article-title":"Inhibition of protein kinase C\u03b5 prevents hepatic insulin resistance in nonalcoholic fatty liver disease","volume":"117","author":"Samuel","year":"2007","journal-title":"J. Clin. Invest."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"16381","DOI":"10.1073\/pnas.1113359108","article-title":"Cellular mechanism of insulin resistance in nonalcoholic fatty liver disease","volume":"108","author":"Kumashiro","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1053\/j.gastro.2012.03.003","article-title":"Intrahepatic diacylglycerol content is associated with hepatic insulin resistance in obese subjects","volume":"142","author":"Magkos","year":"2012","journal-title":"Gastroenterology"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/hep.26672","article-title":"Nonalcoholic Fatty Liver Disease, Hepatic Insulin Resistance, and Type 2 Diabetes","volume":"9","author":"Birkenfeld","year":"2014","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"7933","DOI":"10.1016\/S0021-9258(19)39021-0","article-title":"1,2-Diacylglycerol and ceramide levels in rat skeletal muscle and liver in vivo. Studies with insulin, exercise, muscle denervation, and vasopressin","volume":"265","author":"Turinsky","year":"1990","journal-title":"J. Biol. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.cmet.2012.04.002","article-title":"A ceramide-centric view of insulin resistance","volume":"15","author":"Chavez","year":"2012","journal-title":"Cell Metab."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1126\/science.7678183","article-title":"Adipose expression of tumor necrosis factor-alpha: Direct role in obesity-linked insulin resistance","volume":"259","author":"Hotamisligil","year":"1993","journal-title":"Science"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2409","DOI":"10.1172\/JCI117936","article-title":"Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance","volume":"95","author":"Hotamisligil","year":"1995","journal-title":"J. Clin. Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrm2327","article-title":"Mechanisms of disease: Molecular and metabolic mechanisms of insulin resistance and beta-cell failure in type 2 diabetes","volume":"9","author":"Muoio","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nm1166","article-title":"Local and systemic insulin resistance resulting from hepatic activation of IKK-\u03b2 and NF-\u03baB","volume":"11","author":"Cai","year":"2005","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/liv.12645","article-title":"Blockade of interleukin 6 signalling ameliorates systemic insulin resistance through upregulation of glucose uptake in skeletal muscle and improves hepatic steatosis in high-fat diet fed mice","volume":"35","author":"Yamaguchi","year":"2015","journal-title":"Liver Int."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.3748\/wjg.v20.i7.1768","article-title":"Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1210\/en.2005-0570","article-title":"Saturated fatty acids promote endoplasmic reticulum stress and liver injury in rats with hepatic steatosis","volume":"147","author":"Wang","year":"2006","journal-title":"Endocrinology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1126\/science.1103160","article-title":"Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes","volume":"306","author":"Ozcan","year":"2004","journal-title":"Science"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1053\/j.gastro.2007.10.039","article-title":"Activation and dysregulation of the unfolded protein response in nonalcoholic fatty liver disease","volume":"134","author":"Puri","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2337\/db08-1220","article-title":"Endoplasmic reticulum stress is reduced in tissues of obese subjects after weight loss","volume":"58","author":"Gregor","year":"2009","journal-title":"Diabetes"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1126\/science.1128294","article-title":"Chemical chaperones reduce ER stress and restore glucose homeostasis in a mouse model of type 2 diabetes","volume":"313","author":"Ozcan","year":"2006","journal-title":"Science"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.2337\/db10-0308","article-title":"Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women","volume":"59","author":"Kars","year":"2010","journal-title":"Diabetes"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"4995","DOI":"10.3390\/nu7064995","article-title":"Hepatic steatosis as a marker of metabolic dysfunction","volume":"7","author":"Fabbrini","year":"2015","journal-title":"Nutrients"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1002\/hep.23280","article-title":"Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications","volume":"51","author":"Fabbrini","year":"2010","journal-title":"Hepatology"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1172\/JCI21047","article-title":"Splanchnic lipolysis in human obesity","volume":"113","author":"Nielsen","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1038\/oby.2009.224","article-title":"Relationship between body fat mass and free fatty acid kinetics in men and women","volume":"17","author":"Mittendorfer","year":"2009","journal-title":"Obesity"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S1262-3636(07)70061-7","article-title":"Contribution of hepatic de novo lipogenesis and reesterification of plasma non esterified fatty acids to plasma triglyceride synthesis during non-alcoholic fatty liver disease","volume":"29","author":"Diraison","year":"2003","journal-title":"Diabetes Metab."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"12587","DOI":"10.1073\/pnas.0705408104","article-title":"The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome","volume":"104","author":"Petersen","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/j.1742-4658.2010.07947.x","article-title":"Fatty acid omega-oxidation as a rescue pathway for fatty acid oxidation disorders in humans","volume":"278","author":"Wanders","year":"2011","journal-title":"FEBS J."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/dmr.5610050305","article-title":"Regulation of ketogenesis and the renaissance of carnitine palmitoyltransferase","volume":"5","author":"McGarry","year":"1989","journal-title":"Diabetes Metab. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1089\/ars.2012.4875","article-title":"Mitochondrial fatty acid oxidation in obesity","volume":"19","author":"Serra","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17075","DOI":"10.1073\/pnas.0707060104","article-title":"Mitochondrial dysfunction due to long-chain Acyl-CoA dehydrogenase deficiency causes hepatic steatosis and hepatic insulin resistance","volume":"104","author":"Zhang","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/j.bbalip.2014.09.001","article-title":"Creatine reduces hepatic TG accumulation in hepatocytes by stimulating fatty acid oxidation","volume":"1841","author":"Kelly","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0168-8278(99)80033-6","article-title":"Mitochondrial abnormalities in non-alcoholic steatohepatitis","volume":"31","author":"Caldwell","year":"1999","journal-title":"J. Hepatol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/gast.2001.23256","article-title":"Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities","volume":"120","author":"Sanyal","year":"2001","journal-title":"Gastroenterology"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/hep.1840380426","article-title":"Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis","volume":"38","author":"Martin","year":"2003","journal-title":"Hepatology"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.282.17.1659","article-title":"Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: A pilot study","volume":"282","author":"Chatham","year":"1999","journal-title":"JAMA"},{"key":"ref_54","first-page":"351","article-title":"Re-evaluation of fatty acid metabolism-related gene expression in nonalcoholic fatty liver disease","volume":"20","author":"Kohjima","year":"2007","journal-title":"Int. J. Mol. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1097\/00041433-200104000-00008","article-title":"Very-low-density lipoprotein assembly and secretion","volume":"12","author":"Shelness","year":"2001","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0022-2275(20)38425-X","article-title":"Plasma very low density lipoproteins contain a single molecule of apolipoprotein B","volume":"29","author":"Elovson","year":"1988","journal-title":"J. Lipid Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1097\/00041433-199906000-00006","article-title":"Understanding coronary heart disease as a consequence of defective regulation of apolipoprotein B metabolism","volume":"10","author":"Packard","year":"1999","journal-title":"Curr. Opin. Lipidol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1053\/j.gastro.2007.11.038","article-title":"Alterations in adipose tissue and hepatic lipid kinetics in obese men and women with nonalcoholic fatty liver disease","volume":"134","author":"Fabbrini","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1161\/ATVBAHA.109.202275","article-title":"Nonalcoholic fatty liver disease as the transducer of hepatic oversecretion of very-low-density lipoprotein-apolipoprotein B-100 in obesity","volume":"30","author":"Chan","year":"2010","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1172\/JCI6246","article-title":"Disruption of LDL receptor gene in transgenic SREBP-1a mice unmasks hyperlipidemia resulting from production of lipid-rich VLDL","volume":"103","author":"Horton","year":"1999","journal-title":"J. Clin. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1053\/j.gastro.2015.09.003","article-title":"Physiological Mechanisms of Weight Gain-Induced Steatosis in People With Obesity","volume":"150","author":"Fabbrini","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.tem.2015.11.008","article-title":"The role of cholesterol in the pathogenesis of NASH","volume":"27","author":"Ioannou","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_63","first-page":"1393","article-title":"Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis","volume":"14","author":"Larter","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.jhep.2008.12.016","article-title":"Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH","volume":"50","author":"Caballero","year":"2009","journal-title":"J. Hepatol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"9895176","DOI":"10.1155\/2016\/9895176","article-title":"Liver Cholesterol Overload Aggravates Obstructive Cholestasis by Inducing Oxidative Stress and Premature Death in Mice","volume":"2016","author":"Monte","year":"2016","journal-title":"Oxid. Med. Cell. Longev."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)80213-5","article-title":"The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor","volume":"89","author":"Brown","year":"1997","journal-title":"Cell"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI200422422","article-title":"Molecular mediators of hepatic steatosis and liver injury","volume":"114","author":"Browning","year":"2004","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1172\/JCI0215593","article-title":"SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver","volume":"109","author":"Horton","year":"2002","journal-title":"J. Clin. Investig."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.tem.2012.06.003","article-title":"New insights into ER stress-induced insulin resistance","volume":"23","author":"Flamment","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/hep.26604","article-title":"Free cholesterol accumulation in hepatic stellate cells: mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice","volume":"59","author":"Tomita","year":"2014","journal-title":"Hepatology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.cmet.2006.07.006","article-title":"Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis","volume":"4","author":"Mari","year":"2006","journal-title":"Cell Metab."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.febslet.2010.01.046","article-title":"Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice","volume":"584","author":"Wouters","year":"2010","journal-title":"FEBS Lett."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4419-6741-1_1","article-title":"An overview of sphyngolipid metabolism: from synthesis to breakdown","volume":"688","author":"Gault","year":"2010","journal-title":"Adv. Exp. Med. Biol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"41231","DOI":"10.1038\/srep41231","article-title":"Mechanistic interplay between ceramide and insulin resistance","volume":"7","author":"Reali","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"G959","DOI":"10.1152\/ajpgi.00395.2013","article-title":"Pharmacological ceramide reduction alleviates alcohol-induced steatosis and hepatomegaly in adiponectin knockout mice","volume":"306","author":"Correnti","year":"2014","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1096\/fj.201601156R","article-title":"Ceramides and mitochondrial fatty acid oxidation in obesity","volume":"31","author":"Fucho","year":"2017","journal-title":"FASEB J."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.tem.2012.04.005","article-title":"Role of ceramides in nonalcoholic fatty liver disease","volume":"23","author":"Pagadala","year":"2012","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1542\/peds.2007-2329C","article-title":"Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report","volume":"120","author":"Barlow","year":"2007","journal-title":"Pediatrics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1097\/MPG.0b013e31826d3c62","article-title":"Childhood obesity for pediatric gastroenterologists","volume":"56","author":"Huang","year":"2013","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa066254","article-title":"Effects of bariatric surgery on mortality in Swedish obese subjects","volume":"357","author":"Narbro","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1440-1797.2012.01649.x","article-title":"Acute oxalate nephropathy secondary to orlistat-induced enteric hyperoxaluria","volume":"18","author":"Kwan","year":"2013","journal-title":"Nephrology"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"791","DOI":"10.2174\/1389557514666141013125101","article-title":"Long chain omega-3 polyunsaturated fatty acids in pediatric metabolic syndrome","volume":"14","author":"Pacifico","year":"2014","journal-title":"Mini Rev. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1093\/ajcn\/77.2.300","article-title":"Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicron remnants in men with visceral obesity","volume":"77","author":"Chan","year":"2003","journal-title":"Am. J. Clin. Nutr."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"5862","DOI":"10.1073\/pnas.0707460104","article-title":"Presecretory oxidation, aggregation, and autophagic destruction of apoprotein-B: a pathway for late-stage quality control","volume":"105","author":"Pan","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1194\/jlr.M016931","article-title":"Different fatty acids inhibit apoB100 secretion by different pathways: unique roles for ER stress, ceramide, and autophagy","volume":"52","author":"Caviglia","year":"2011","journal-title":"J. Lipid Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1373\/clinchem.2004.040477","article-title":"Apolipoprotein C-III, n-3 polyunsaturated fatty acid, and \u201cinsulin-resistant\u201d T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction","volume":"51","author":"Olivieri","year":"2005","journal-title":"Clin. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1136\/adc.2010.192401","article-title":"Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: Double-blind randomised controlled clinical trial","volume":"96","author":"Nobili","year":"2011","journal-title":"Arch. Dis. Child."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/j.numecd.2012.10.010","article-title":"Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children","volume":"23","author":"Nobili","year":"2013","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Nobili, V., Carpino, G., Alisi, A., De Vito, R., Franchitto, A., Alpini, G., Onori, P., and Gaudio, E. (2014). Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0088005"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.numecd.2015.04.003","article-title":"A double-blind, placebo-controlled randomized trial to evaluate the efficacy of docosahexaenoic acid supplementation on hepatic fat and associated cardiovascular risk factors in overweight children with nonalcoholic fatty liver disease","volume":"25","author":"Pacifico","year":"2015","journal-title":"Nutr. Metab. Cardiovasc. Dis."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.coph.2017.04.005","article-title":"Dyslipidemia management update","volume":"33","author":"Chang","year":"2017","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1567-5688(15)50007-X","article-title":"The effect of ezetimibe on NAFLD","volume":"17","author":"Averna","year":"2015","journal-title":"Atheroscler. Suppl."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/hepr.12092","article-title":"Novel effect of ezetimibe to inhibit the development of non-alcoholic fatty liver disease in Fatty Liver Shionogi mouse","volume":"44","author":"Wang","year":"2014","journal-title":"Hepatol. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1517\/14740338.2015.1063613","article-title":"Evaluating the safety of Liptruzet (ezetimibe and atorvastatin): What are the potential benefits beyond low-density lipoprotein cholesterol-lowering effect?","volume":"14","author":"Husain","year":"2015","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00125-013-3149-9","article-title":"The effects of ezetimibe on non-alcoholic fatty liver disease and glucose metabolism: A randomised controlled trial","volume":"57","author":"Takeshita","year":"2014","journal-title":"Diabetologia"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Chong, L.W., Hsu, Y.C., Lee, T.F., Lin, Y., Chiu, Y.T., Yang, K.C., Wu, J.C., and Huang, Y.T. (2015). Fluvastatin attenuates hepatic steatosis-induced fibrogenesis in rats through inhibiting paracrine effect of hepatocyte on hepatic stellate cells. BMC Gastroenterol., 15.","DOI":"10.1186\/s12876-015-0248-8"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1124\/jpet.302.1.232","article-title":"Atorvastatin treatment induced peroxisome proliferator-activated receptor \u03b1 expression and decreased plasma nonesterified fatty acids and liver triglyceride in fructose-fed rats","volume":"302","author":"Roglans","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s11745-003-1093-x","article-title":"Pitavastatin ameliorates severe hepatic steatosis in aromatase-deficient (Ar\u2212\/\u2212) mice","volume":"38","author":"Egawa","year":"2003","journal-title":"Lipids"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1002\/hep.25762","article-title":"The diagnosis and management of non-alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association","volume":"55","author":"Chalasani","year":"2012","journal-title":"Hepatology"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.jpeds.2016.12.078","article-title":"Cholesterol Screening and Treatment Practices and Preferences: A Survey of United States Pediatricians","volume":"185","author":"Rodday","year":"2017","journal-title":"J. Pediatr."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1194\/jlr.R024794","article-title":"Bile acid receptors as targets for the treatment of dyslipidemia and cardiovascular disease","volume":"53","author":"Porez","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e005","DOI":"10.1621\/nrs.08005","article-title":"Deciphering the nuclear bile acid receptor FXR paradigm","volume":"8","author":"Modica","year":"2010","journal-title":"Nucl. Recept. Signal."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/nrm3312","article-title":"Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR","volume":"13","author":"Calkin","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.cmet.2013.03.013","article-title":"Pleiotropic roles of bile acids in metabolism","volume":"17","author":"Tarling","year":"2013","journal-title":"Cell Metab."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1194\/jlr.M001602","article-title":"FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa\/fa) obese rats","volume":"51","author":"Cipriani","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial","volume":"385","author":"Loomba","year":"2015","journal-title":"Lancet"}],"container-title":["Children"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9067\/4\/6\/46\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T18:38:09Z","timestamp":1760207889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9067\/4\/6\/46"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,6]]},"references-count":107,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2017,6]]}},"alternative-id":["children4060046"],"URL":"https:\/\/doi.org\/10.3390\/children4060046","relation":{},"ISSN":["2227-9067"],"issn-type":[{"value":"2227-9067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,6]]}}}